Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales

Novo Nordisk A/S (NVO) reported fourth-quarter 2023 earnings of 71 cents per American Depositary Receipt (ADR), which surpassed the Zacks Consensus Estimate of 66 cents. The company had reported earnings of 41 cents per ADR in the year-ago quarter.Revenues of $9.51 billion increased 37% in Danish kroner (DKK) and were up 43% at constant exchange rate (CER) in the reported quarter. Total revenues also beat the Zacks Consensus Estimate of$ 9.14 billion. The year-over-year increase in revenues was driven by hi ...